Zifanocycline (KBP-7072) TFA is a semi-synthetic aminomethylcycline antibiotic with oral bioavailability, targeting bacterial ribosomes to impede their function. Displaying a broad spectrum of in vitro antimicrobial efficacy, it combats both Gram-positive and Gram-negative bacteria, inclusive of numerous multidrug-resistant strains. Its clinical investigations focus on efficacies in treating acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, and complicated intra-abdominal infections [1] [2].